Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2024 16:05 ET | Source: 89bio, Inc.

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
May 09, 2024 16:05 ET | Source: 89bio, Inc.

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this...
May 08, 2024 16:05 ET | Source: 89bio, Inc.

89bio to Participate in the BofA Securities 2024 Health Care Conference

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
May 02, 2024 16:05 ET | Source: 89bio, Inc.

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
April 17, 2024 16:05 ET | Source: 89bio, Inc.

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
April 05, 2024 16:05 ET | Source: 89bio, Inc.

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...
March 27, 2024 08:00 ET | Source: 89bio, Inc.

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and...
March 12, 2024 08:00 ET | Source: 89bio, Inc.

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

—Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second...
March 08, 2024 16:05 ET | Source: 89bio, Inc.

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...
March 05, 2024 16:05 ET | Source: 89bio, Inc.

89bio to Participate in the Leerink Partners Global Biopharma Conference

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...